### Glucoft, Josh

From:	Wang, Kevin
Sent:	Thursday, April 12, 2018 3:45 PM
То:	~Manes, Austin
Cc:	~Andre, Paul; ~Kobialka, Lisa; ~Hannah, James; ~Kastens, Kristopher; Kagan, Jonathan;
	Carson, Rebecca; Glucoft, Josh; Holland, Eileen; Curran, Casey
Subject:	RE: Finjan v. Juniper - 3:17-cv-05659-WHA

**EXHIBIT 1** 

Austin,

Juniper does have a specific concern regarding Dr. Cole and the ethical rules, specifically regarding the prohibitions against contacting represented parties. Juniper does not have detailed knowledge of all of Dr. Cole's prior work with Finjan so it is imperative that Finjan confirms this. I would think this request is non-controversial and it is unclear why Finjan continues to evade the question. If you can represent that Dr. Cole has abided by all ethical rules in his prior work for Finjan, including prohibitions against contacting represented parties, please do so by 5:00pm today. If you cannot make that representation, then please let us know.

Thanks. Kevin

From: Manes, Austin [mailto:AManes@KRAMERLEVIN.com] Sent: Thursday, April 12, 2018 2:59 PM To: Wang, Kevin <kwang@irell.com> Cc: ~Andre, Paul <pandre@kramerlevin.com>; ~Kobialka, Lisa <lkobialka@kramerlevin.com>; ~Hannah, James <jhannah@kramerlevin.com>; ~Kastens, Kristopher <kkastens@kramerlevin.com>; Kagan, Jonathan <JKagan@irell.com>; Carson, Rebecca <RCarson@irell.com>; Glucoft, Josh <JGlucoft@irell.com>; Holland, Eileen <EHolland@irell.com>; Curran, Casey <ccurran@irell.com> Subject: RE: Finjan v. Juniper - 3:17-cv-05659-WHA

Kevin,

If you have a specific concern regarding Dr. Cole and the ethical rules, or some particular incident in mind, let me know and I'm happy to discuss it with you. Otherwise, I don't think asking a baseless, open-ended question is productive as we can ask the same for every member of your team.

Austin

Austin Manes Associate

Kramer Levin Naftalis & Frankel LLP 990 Marsh Road, Menlo Park, California 94025 **T** 650.752.1718

This communication (including any attachments) is intended solely for the recipient(s) named above and may contain information that is confidential, privileged or legally protected. Any unauthorized use or dissemination of this communication is strictly prohibited. If you have received



### Case 3:17-cv-05659-WHA Document 54-1 Filed 04/13/18 Page 2 of 7

this communication in error, please immediately notify the sender by return e-mail message and delete all copies of the original communication. Thank you for your cooperation.

From: Wang, Kevin <<u>kwang@irell.com</u>>
Sent: Wednesday, April 11, 2018 2:54 PM
To: Manes, Austin <<u>AManes@KRAMERLEVIN.com</u>>
Cc: Andre, Paul <<u>PAndre@KRAMERLEVIN.com</u>>; Kobialka, Lisa <<u>LKobialka@KRAMERLEVIN.com</u>>; Hannah, James
<<u>JHannah@KRAMERLEVIN.com</u>>; Kastens, Kris <<u>KKastens@KRAMERLEVIN.com</u>>; Kagan, Jonathan <<u>JKagan@irell.com</u>>;
Carson, Rebecca <<u>RCarson@irell.com</u>>; Glucoft, Josh <<u>JGlucoft@irell.com</u>>; Holland, Eileen <<u>EHolland@irell.com</u>>;
Curran, Casey <<u>ccurran@irell.com</u>>
Subject: [EXTERNAL] RE: Finjan v. Juniper - 3:17-cv-05659-WHA

Austin,

The reason for asking is to simply confirm whether Dr. Cole has abided by all applicable ethical rules in his prior work for Finjan.

As we've stated, Dr. Cole is not permitted to review Juniper's Protected Material under section 2.7 of the Model Protective Order. Finjan insists on deviating from the governing Protective Order, claiming that Dr. Cole has some level of trustworthiness that somehow exempts him from the established rules in this district. The issue of whether he has complied with all ethical rules in his past work is relevant to the issue of his trustworthiness. As such, please confirm whether Dr. Cole has abided by all applicable ethical rules in his prior work for Finjan, including prohibitions against contacting represented parties.

Thanks, Kevin

From: Manes, Austin [mailto:AManes@KRAMERLEVIN.com]
Sent: Tuesday, April 10, 2018 5:35 PM
To: Wang, Kevin
Cc: ~Andre, Paul; ~Kobialka, Lisa; ~Hannah, James; ~Kastens, Kristopher; Kagan, Jonathan; Carson, Rebecca; Glucoft, Josh; Holland, Eileen; Curran, Casey
Subject: RE: Finjan v. Juniper - 3:17-cv-05659-WHA

Kevin,

What is your reason for asking this question? Is this the basis for Juniper's objection to Dr. Cole? Or is it his work for McAfee 8 years ago?

Austin

Austin Manes Associate

DOCKET

Kramer Levin Naftalis & Frankel LLP 990 Marsh Road, Menlo Park, California 94025 **T** 650.752.1718

### Case 3:17-cv-05659-WHA Document 54-1 Filed 04/13/18 Page 3 of 7

This communication (including any attachments) is intended solely for the recipient(s) named above and may contain information that is confidential, privileged or legally protected. Any unauthorized use or dissemination of this communication is strictly prohibited. If you have received this communication in error, please immediately notify the sender by return e-mail message and delete all copies of the original communication. Thank you for your cooperation.

From: Wang, Kevin <<u>kwang@irell.com</u>>
Sent: Tuesday, April 10, 2018 5:03 PM
To: Manes, Austin <<u>AManes@KRAMERLEVIN.com</u>>
Cc: Andre, Paul <<u>PAndre@KRAMERLEVIN.com</u>>; Kobialka, Lisa <<u>LKobialka@KRAMERLEVIN.com</u>>; Hannah, James
<<u>JHannah@KRAMERLEVIN.com</u>>; Kastens, Kris <<u>KKastens@KRAMERLEVIN.com</u>>; Kagan, Jonathan <<u>JKagan@irell.com</u>>;
Carson, Rebecca <<u>RCarson@irell.com</u>>; Glucoft, Josh <<u>JGlucoft@irell.com</u>>; Holland, Eileen <<u>EHolland@irell.com</u>>;
Curran, Casey <<u>ccurran@irell.com</u>>
Subject: [EXTERNAL] Re: Finjan v. Juniper - 3:17-cv-05659-WHA

Austin,

Finjan has not responded regarding whether Dr. Cole has abided by all applicable ethical rules in his prior work for Finjan, including prohibitions against contacting represented parties. Please confirm whether Finjan contends that Dr. Cole has abided by all applicable ethical rules.

Thanks,

Kevin

On Apr 5, 2018, at 6:40 PM, Wang, Kevin <<u>kwang@irell.com</u>> wrote:

Austin,

Thank you for conferring today regarding Dr. Cole.

Please also confirm that Dr. Cole has abided by all applicable ethical rules in his prior work for Finjan, including prohibitions against contacting represented parties.

Thanks, Kevin

 From: Manes, Austin [mailto:AManes@KRAMERLEVIN.com]

 Sent: Wednesday, April 4, 2018 3:29 PM

 To: Wang, Kevin <<u>kwang@irell.com</u>>

 Cc: ~Andre, Paul <<u>pandre@kramerlevin.com</u>>; ~Kobialka, Lisa <<u>lkobialka@kramerlevin.com</u>>; ~Hannah,

 James <<u>jhannah@kramerlevin.com</u>>; ~Kastens, Kristopher <<u>kkastens@kramerlevin.com</u>>; Kagan,

 Jonathan <<u>JKagan@irell.com</u>>; Carson, Rebecca <<u>RCarson@irell.com</u>>; Glucoft, Josh

 <JGlucoft@irell.com>; Holland, Eileen <<u>EHolland@irell.com</u>>; Curran, Casey <<u>ccurran@irell.com</u>>

 Subject: RE: Finjan v. Juniper - 3:17-cv-05659-WHA

Kevin,

DOCKF

I'll call you at noon tomorrow.

Austin

Austin Manes

Associate

Kramer Levin Naftalis & Frankel LLP 990 Marsh Road, Menlo Park, California 94025 **T** 650.752.1718

This communication (including any attachments) is intended solely for the recipient(s) named above and may contain information that is confidential, privileged or legally protected. Any unauthorized use or dissemination of this communication is strictly prohibited. If you have received this communication in error, please immediately notify the sender by return e-mail message and delete all copies of the original communication. Thank you for your cooperation.

From: Wang, Kevin <<u>kwang@irell.com</u>>
Sent: Wednesday, April 4, 2018 3:25 PM
To: Manes, Austin <<u>AManes@KRAMERLEVIN.com</u>>
Cc: Andre, Paul <<u>PAndre@KRAMERLEVIN.com</u>>; Kobialka, Lisa <<u>LKobialka@KRAMERLEVIN.com</u>>;
Hannah, James <<u>JHannah@KRAMERLEVIN.com</u>>; Kastens, Kris <<u>KKastens@KRAMERLEVIN.com</u>>; Kagan, Jonathan <<u>JKagan@irell.com</u>>; Carson, Rebecca <<u>RCarson@irell.com</u>>; Glucoft, Josh
<<u>JGlucoft@irell.com</u>>; Holland, Eileen <<u>EHolland@irell.com</u>>; Curran, Casey <<u>ccurran@irell.com</u>>
Subject: [EXTERNAL] RE: Finjan v. Juniper - 3:17-cv-05659-WHA

Austin,

There are several outstanding issues we have not met and conferred on. Finjan has not directly addressed several issues brought up by Juniper, including why Finjan continues to insist on disclosing Protected Material to a former employee of a competitor when Finjan has already designated three other experts to which Juniper has not objected. Many of these experts have also worked with Finjan in the past. Moreover, Finjan now claims that Juniper is objecting as a pretext to drive up costs for Finjan. While this is simply not true, you have also not given us any information relating to these alleged costs. If you provide that information we can discuss it.

Regardless, in an effort to compromise we propose that Dr. Cole agrees to not work for a Juniper competitor for the next 5 years, either directly or indirectly. This would alleviate some of Juniper's concern by firmly showing Dr. Cole "is not anticipated to become an employee of a Party or a Party's competitor" pursuant to section 2.7 of the governing Model Protective Order.

We cannot meet and confer today, but you would presumably need time to consider and discuss this with Dr. Cole. I can confer with you either tomorrow at noon or early next week. Please let me know, thank you.

Kevin

RM

DOCKE

From: Manes, Austin [mailto:AManes@KRAMERLEVIN.com] Sent: Wednesday, April 4, 2018 8:34 AM To: Wang, Kevin <<u>kwang@irell.com</u>>

### Case 3:17-cv-05659-WHA Document 54-1 Filed 04/13/18 Page 5 of 7

James <<u>ihannah@kramerlevin.com</u>>; ~Kastens, Kristopher <<u>kkastens@kramerlevin.com</u>>; Kagan, Jonathan <<u>JKagan@irell.com</u>>; Carson, Rebecca <<u>RCarson@irell.com</u>>; Glucoft, Josh <<u>JGlucoft@irell.com</u>>; Holland, Eileen <<u>EHolland@irell.com</u>>; Curran, Casey <<u>ccurran@irell.com</u>> **Subject:** RE: Finjan v. Juniper - 3:17-cv-05659-WHA

Kevin,

We met and conferred on this issue two weeks ago, during which I fully explained Finjan's position. Juniper hasn't raised any new arguments in multiple emails since. Given the accelerated schedule, Finjan cannot wait until next week to further meet and confer.

If you have something new to add, I am available all day today to discuss this again, except from 11:00 – 11:30. Otherwise, we will seek relief from the Court.

Thanks, Austin

### Austin Manes

Associate

### Kramer Levin Naftalis & Frankel LLP 990 Marsh Road, Menlo Park, California 94025 **T** 650.752.1718

This communication (including any attachments) is intended solely for the recipient(s) named above and may contain information that is confidential, privileged or legally protected. Any unauthorized use or dissemination of this communication is strictly prohibited. If you have received this communication in error, please immediately notify the sender by return e-mail message and delete all copies of the original communication. Thank you for your cooperation.

From: Wang, Kevin <<u>kwang@irell.com</u>>
Sent: Tuesday, April 3, 2018 6:59 PM
To: Manes, Austin <<u>AManes@KRAMERLEVIN.com</u>>
Cc: Andre, Paul <<u>PAndre@KRAMERLEVIN.com</u>>; Kobialka, Lisa <<u>LKobialka@KRAMERLEVIN.com</u>>;
Hannah, James <<u>JHannah@KRAMERLEVIN.com</u>>; Kastens, Kris <<u>KKastens@KRAMERLEVIN.com</u>>; Kagan, Jonathan <<u>JKagan@irell.com</u>>; Carson, Rebecca <<u>RCarson@irell.com</u>>; Glucoft, Josh<<<u>JGlucoft@irell.com</u>>; Holland, Eileen <<u>EHolland@irell.com</u>>; Curran, Casey <<u>ccurran@irell.com</u>>
Subject: [EXTERNAL] RE: Finjan v. Juniper - 3:17-cv-05659-WHA

### Austin,

Juniper disagrees with many of Finjan's assertions, including that Juniper's objection is a pretext to increase the cost of litigation for Finjan. But rather than speaking through e-mail, we believe it would be more productive at this point to simply meet and confer. Are you available to take a call next week? Please let me know, thank you.

### Kevin

From: Manes, Austin [mailto:AManes@KRAMERLEVIN.com] Sent: Monday, April 2, 2018 7:13 PM To: Wang, Kevin <<u>kwang@irell.com</u>>



## DOCKET A L A R M



# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## **Real-Time Litigation Alerts**



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## **Advanced Docket Research**



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## **Analytics At Your Fingertips**



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

### API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

### LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

### FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

### E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.